Antifungal Therapy for Invasive Aspergillosis

被引:0
|
作者
Khan, Seher A. [1 ]
机构
[1] Lake Erie Coll Osteopath Med, Sch Pharm, Pharmaceut Sci, Erie, PA 16509 USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Invasive aspergillosis is a lethal fungal infection that usually affects the lung cells of immunocompromised hosts. If left untreated, the disease can spread into other vital organs, including the brain and the heart. In recent years, the frequency of this fatal condition has increased significantly owing to greater numbers of patients with neutropenia, malignancies, organ transplants, or advanced AIDS. Antifungal agents continue to be the mainstay of treatment to reduce the fungal burden. Amphotericin B (AmB), a polyene antibiotic that previously was used to treat this condition, has produced variable responses and serious adverse effects. Current treatment options utilize different azole compounds, lipid formulations of AmB, and echinocandins. These newer broad-spectrum antifungals are well tolerated and produce desirable therapeutic outcomes.
引用
收藏
页码:HS2 / HS5
页数:4
相关论文
共 50 条
  • [41] Association Between the Need to Change Initial Antifungal Therapy and Treatment Costs in Patients With Invasive Aspergillosis
    Alexander, Barbara D.
    Johnson, Melissa
    Bresnik, Mark
    Anupindi, Vamshi Ruthwik
    Pizzicato, Lia
    Dekoven, Mitchell
    Lovelace, Belinda
    Coleman, Craig, I
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (01):
  • [42] Combination antifungal therapy for invasive aspergillosis: a randomized trial (vol 162, pg 81, 2015)
    Marr, K. A.
    Schlamm, H. T.
    Herbrecht, R.
    Rottinghaus, S. T.
    Bow, E. J.
    Cornely, O. A.
    ANNALS OF INTERNAL MEDICINE, 2015, 162 (06) : 463 - 463
  • [43] Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis
    Kovanda, Laura L.
    Desai, Amit V.
    Hope, William W.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 (02) : 143 - 151
  • [44] Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis
    Liu, Ao
    Xiong, Liubo
    Wang, Lian
    Zhuang, Han
    Gan, Xiao
    Zou, Mengying
    Wang, Xiaoming
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [45] Combination antifungal therapy for invasive aspergillosis infection in liver transplant recipients: Report of two patients
    Bajjoka, IE
    Bailey, EM
    Vazquez, JA
    Abouljoud, MS
    PHARMACOTHERAPY, 1999, 19 (01): : 118 - 123
  • [46] Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy
    Maertens, J
    Raad, I
    Petrikkos, G
    Boogaerts, M
    Selleslag, D
    Petersen, FB
    Sable, CA
    Kartsonis, NA
    Ngai, A
    Taylor, A
    Patterson, TF
    Denning, DW
    Walsh, TJ
    CLINICAL INFECTIOUS DISEASES, 2004, 39 (11) : 1563 - 1571
  • [47] Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis
    Laura L. Kovanda
    Amit V. Desai
    William W. Hope
    Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44 : 143 - 151
  • [48] Optimized Antifungal Therapy for Chronic Pulmonary Aspergillosis
    Yagi, Yusuke
    Yamagishi, Yuka
    Hamada, Yukihiro
    MEDICAL MYCOLOGY JOURNAL, 2024, 65 (03) : 59 - 65
  • [49] Evaluation of antifungal drugs by an invasive aspergillosis on-a-chip model
    Hoang, M.
    Cseresnyes, Z.
    Hartung, S.
    Schuck, N.
    Ruethrich, M. M.
    Rennert, K.
    Kloss, F.
    Mosig, A. S.
    von Lilienfeld-Toal, M.
    Figge, M. T.
    MYCOSES, 2020, 63 : 34 - 34
  • [50] Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis
    Rieg, Gunter
    Spellberg, Brad
    Schwartz, Julie
    Fu, Yue
    Edwards, John E., Jr.
    Sheppard, Donald C.
    Ibrahim, Ashraf S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (08) : 2895 - 2896